scm logo

SCM Life Science announced on the 25th that it has attracted 5.5 billion won worth of investment from CCM Duopharma Biotech Berhard (hereinafter referred to as CCM Duopharma), Malaysia's largest pharmaceutical company. 

SCM Life Science is a stem cell therapy company with original technology in the field of high purity separation and culture of adult stem cells, attracting 38.6 billion won worth of Series C investment from domestic and foreign investors such as KB Investment and Yozma Group in September. Following attracting investment, CCM Duofarma's investment agreement succeeded in attracting a total of 44.1 billion won and a total of 7.5 billion won from overseas companies alone.

The investment agreement is expected to pave the way for SCM Life Science to enter the Southeast Asian market and gain momentum in SCM Life Science' global expansion.

CCM Duo Pharma, a subsidiary of CCM, a Malaysian state-run company, is the largest pharmaceutical company in Malaysia to receive the world's first halal pharmaceutical standard certification in the field of pharmaceuticals and produces more than 200 generic drugs.

Lee Byung-gun, CEO of SCM Life Science, said, "This investment agreement has recognized the value of the original technology for stem cell therapy owned by SCM Life Science. We expect it to be an opportunity for SCM Life Science to take a step further in its global expansion through exchanges following CCM Duofarma's investment attraction, he said.

Leonard Arif Abdul Shatar, CEO of CCM Duofharma, said, "CCM Duofharma was closely considering strategic investments in the high-tech regenerative medical industry using stem cells that meet its new market entry strategy.

Meanwhile, SCM Life Science is focusing on the development of next-generation stem cell treatments for autoimmune diseases, an intractable disease, and has continued research for more than 10 years based on its own source technology for adult mesenchyma stem cell separation and culture. Through this, patents have been registered in major countries, including the United States, the EU, Japan, and China, and are currently focusing on developing cell therapies such as chronic and acute Graft versus host disease (GVHD), severe acute pancreatitis, severe atopic dermatitis, and severe cirrhosis.